EDIT
Editas Medicine Inc
2.70$
-0.7%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1,125.5% | +53.4% | +62.9% | +12.6% | +21.1% | +12.5% | +18.3% | -24.1% | -2.9% | -31.6% | -45.4% | |
| – | +1,253.0% | +29.1% | +77.5% | +12.8% | +23.8% | -9.6% | +21.1% | -29.7% | -4.5% | -15.1% | -43.4% | |
| – | +1,247.8% | +29.4% | -20.9% | -8.1% | +76.7% | -41.4% | +45.7% | -30.5% | -12.6% | +6.4% | +11.5% | |
| – | +1,247.8% | +29.4% | +77.6% | +12.1% | +23.9% | -12.0% | +24.3% | -31.1% | -6.1% | -16.5% | -45.7% | |
| – | +0.0% | -91.4% | +671.6% | -95.6% | +1,293.3% | +1,346.9% | -95.6% | +1,827.0% | +98.0% | +59.7% | -6.7% | |
| – | – | +113.1% | +12.2% | +56.5% | – | – | – | – | – | – | – | |
| – | +91.5% | +1,795.7% | -2.3% | +2.0% | -1.5% | -64.6% | +22.1% | -9.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +746.0% | -59.3% | +74.7% | +11.5% | +33.8% | -27.4% | -30.8% | +24.1% | -2.3% | +38.2% | -23.2% | |
| – | +12.4% | +377.7% | +11.0% | -2.2% | +67.0% | -2.9% | -19.5% | +28.2% | +5.2% | +22.2% | -40.1% | |
| – | +14,825.4% | +0.0% | -25.0% | +70.8% | -54.7% | +17.4% | +51.4% | +7.5% | +118.1% | -39.4% | -24.7% | |
| – | -46.8% | +236.0% | -13.4% | +32.5% | +9.7% | +9.7% | -21.2% | +88.3% | -13.1% | -33.6% | -52.6% | |
| – | +10,102.3% | +0.0% | -4.7% | – | – | – | – | – | – | – | – | |
| – | – | – | +54.6% | +13.5% | +11.1% | +50.0% | +40.7% | -34.9% | -3.2% | -61.5% | -79.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1,292.9% | -9.7% | +25.2% | +16.8% | +6.1% | +17.3% | +15.4% | +1.5% | +10.6% | +8.4% | +7.8% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.